Literature DB >> 24771925

Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.

R Kreienberg1, U-S Albert2, M Follmann3, I B Kopp4, T Kühn5, A Wöckel6.   

Abstract

Entities:  

Year:  2013        PMID： 24771925      PMCID： PMC3963234          DOI： 10.1055/s-0032-1328689

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN： 0016-5751            Impact factor:   2.915


× No keyword cloud information.
  281 in total

1.  [Quality control in breast sonography].

Authors:  H Madjar; A Mundinger; F Degenhardt; V Duda; B J Hackelöer; R Osmers
Journal:  Ultraschall Med       Date:  2003-06       Impact factor: 6.548

2.  Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.

Authors:  G W Sledge; P Hu; G Falkson; D Tormey; M Abeloff
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

Review 3.  The effect of overweight and nutrition on prognosis in breast cancer.

Authors:  Dagmar Hauner; Wolfgang Janni; Brigitte Rack; Hans Hauner
Journal:  Dtsch Arztebl Int       Date:  2011-11-25       Impact factor: 5.594

Review 4.  Routinely available indicators of prognosis in breast cancer.

Authors:  D L Page; R A Jensen; J F Simpson
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

5.  Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials.

Authors: 
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

Review 6.  Psychological interventions for women with metastatic breast cancer.

Authors:  A G K Edwards; S Hailey; M Maxwell
Journal:  Cochrane Database Syst Rev       Date:  2004

7.  Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy.

Authors:  Amit K Garg; Julia L Oh; Mary Jane Oswald; Eugene Huang; Eric A Strom; George H Perkins; Wendy A Woodward; T Kuan Yu; Welela Tereffe; Funda Meric-Bernstam; Karin Hahn; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-12       Impact factor: 7.038

Review 8.  Cardiac mortality and morbidity after breast cancer treatment.

Authors:  Eleanor E Harris
Journal:  Cancer Control       Date:  2008-04       Impact factor: 3.302

Review 9.  Reporting clinical outcomes of breast reconstruction: a systematic review.

Authors:  S Potter; A Brigic; P F Whiting; S J Cawthorn; K N L Avery; J L Donovan; J M Blazeby
Journal:  J Natl Cancer Inst       Date:  2010-12-03       Impact factor: 13.506

Review 10.  Single agent versus combination chemotherapy for metastatic breast cancer.

Authors:  Sue Carrick; Sharon Parker; Charlene E Thornton; Davina Ghersi; John Simes; Nicholas Wilcken
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15
View more
  25 in total

1.  iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer?

Authors:  Christina Bluemel; Andreas Cramer; Christoph Grossmann; Georg W Kajdi; Uwe Malzahn; Nora Lamp; Heinz-Jakob Langen; Jan Schmid; Andreas K Buck; Hanns-Jörg Grimminger; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-09       Impact factor: 9.236

2.  Adherence to tamoxifen in breast cancer patients: What role does the pharmacist play in German primary care?

Authors:  Madlene Schulz; Lena Klopp-Schulze; Stefanie Keilhack; Sandra Meyer; Lea Botermann; Charlotte Kloft
Journal:  Can Pharm J (Ott)       Date:  2018-12-20

3.  Supporting breast cancer decisions using formalized guidelines and experts decision patterns: initial prototype and evaluation.

Authors:  Dennis Andrzejewski; Rüdiger Breitschwerdt; Michael Fellmann; Eberhard Beck
Journal:  Health Inf Sci Syst       Date:  2017-10-30

4.  Comparison of Sonography versus Digital Breast Tomosynthesis to Locate Intramammary Marker Clips.

Authors:  R Schulz-Wendtland; P Dankerl; G Dilbat; M Bani; P A Fasching; K Heusinger; M P Lux; C R Loehberg; S M Jud; C Rauh; C M Bayer; M W Beckmann; D L Wachter; M Uder; M Meier-Meitinger; B Brehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-01       Impact factor: 2.915

Review 5.  Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting--a systematic review of systematic reviews.

Authors:  S Tafelski; W Häuser; M Schäfer
Journal:  Schmerz       Date:  2016-02       Impact factor: 1.107

6.  Quality Assurance for Patients with Breast Cancer - the Impact of Clinical Cancer Registries.

Authors:  E C Inwald; M Klinkhammer-Schalke; M Koller; O Ortmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-09       Impact factor: 2.915

7.  Touch Imprint Cytology and Stereotactically-Guided Core Needle Biopsy of Suspicious Breast Lesions: 15-Year Follow-up.

Authors:  R Schulz-Wendtland; P A Fasching; M R Bani; M P Lux; S Jud; C Rauh; C Bayer; D L Wachter; A Hartmann; M W Beckmann; M Uder; C R Loehberg
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-01       Impact factor: 2.915

8.  Evaluation of Newly Adapted Clip Marker System in Ultrasound-Guided Core Needle Biopsy for Suspicion of Breast Cancer.

Authors:  R Schulz-Wendtland; P Dankerl; G Dilbat; M Bani; P A Fasching; K Heusinger; M P Lux; C R Loehberg; S M Jud; C Rauh; C M Bayer; M W Beckmann; M Uder; M Meier-Meitinger; B Brehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-11       Impact factor: 2.915

Review 9.  Local and Systemic Therapies for Breast Cancer Patients: Reducing Short-term Symptoms with the Methods of Integrative Medicine.

Authors:  C C Hack; P Voiß; S Lange; A E Paul; S Conrad; G J Dobos; M W Beckmann; S Kümmel
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-07       Impact factor: 2.915

10.  Radiotherapy of brain metastases from breast cancer: Treatment results and prognostic factors.

Authors:  Julia Kühnöl; Caspar Kühnöl; Dirk Vordermark
Journal:  Oncol Lett       Date:  2016-03-17       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.